Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antineoplastic and immunomodulating drugs
Belvarafenib
Другие языки:

    Belvarafenib

    Подписчиков: 0, рейтинг: 0
    Belvarafenib
    Belvarafenib.svg
    Clinical data
    Other names HM95573

    GDC5573

    RG6185
    Routes of
    administration    		 By mouth
    Identifiers
    • 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C23H16ClFN6OS
    Molar mass 478.93 g·mol−1
    3D model (JSmol)
    • CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N
    • InChI=InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)
    • Key:KVCQTKNUUQOELD-UHFFFAOYSA-N

    Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.



    Новое сообщение